Zynex Retains BUYINS.NET to Surveil Market Maker and Short Sellers

Share Article

Short Squeeze Expected When Stock Crosses Above the $0.66 SqueezeTrigger Price

Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics and compound pharmacy, announced today it has retained Buyins.net to initiate coverage and compliance monitoring, short sale trading statistics and market integrity surveillance on its stock. Buyins.net monitors ZYXI market-makers daily for compliance with Fair Market-Making Requirements, and released its first short sale data report on ZYXI on May 14, 2015. The report indicates a SqueezeTrigger price for all ZYXI shares shorted to be $0.66 per share. To view the report or get a more detailed description of the SqueezeTrigger and other indicators, go to http://www.buyins.net and enter “ZYXI” in the search box.

About BUYINS.NET

BUYINS.NET, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies and comparable valuations. For additional information, please visit: http://www.buyins.net.

About Zynex

Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex operates a non-sterile compound pharmacy providing topical and transdermal pain creams. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: http://www.zynex.com.

Safe Harbor Statement

Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital or augment our liquidity in order to continue our business, the success of our compound pharmacy and international expansion efforts, our ability to engage additional sales representatives, the success of such additional sales representatives, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2014.

Contact:
Brian Alleman
Zynex, Inc.
(303) 703-4906

BUYINS.NET
Thomas Ronk
800-715-9999

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brian Alleman
Zynex, Inc.
+1 (303) 703-4906 Ext: 3322
Email >
Visit website